课题基金 / 基金详情

HTS Molecules Targeting APP 5'untranslated Region(RMI)

HTS Molecules Targeting APP 5'untranslated Region(RMI)
靶向 APP 5非翻译区 (RMI) 的 HTS 分子
批准号:
7021329
负责人:
JACK T ROGERS
金额:
$8.75万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-09-30 至 2008-08-31

项目摘要

项目成果

JACK T ROGERS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The 5' untranslated region of the mRNA for the Alzheimer's Amyloid Precursor Protein (APP 5' UTR) is a key translational regulatory element that sets the amount of APP production in any given cell. IL-1 enhanced the interaction between Iron-regulatory Proteins (IRPs) and APP 5'UTR RNA secondary structure via an Iron responsive Element (IRE). This regulation suggested the APP 5' UTR to be an excellent drug target. Our laboratory gained valuable experience in the field of drug discovery when we screened a library of FDA pre-approved drugs and identified 17 leads that limited APP 5' UTR driven translation using transiently transfected neuroblastoma cells. In secondary western blot-based assays paroxetine (SSRI) and dimercaptopropanol (chelator) selectively reduced APP holoprotein expression. As proof of drug selectivity achieved during the APP 5'UTR screen these 2 hits did not change APLP-1 and APLP-2 expression in SH-SY5Y cells (Payton et al., 2003). A pilot study indicated that Paroxetine reduced the amyloid burden in a transgenic mouse model for AD (TgCRNDS mice). The data to be gathered through this R03 RFA mechanism will assist us to develop our FDA pilot screen to set up a high throughput transfection based screen of an important RNA target. Use of automated equipment for 384 well based screens is now available through our collaboration with the Laboratory of Drug Discovery for Neurodegeneration (LDDN). Our strategy will be to optimize a high throughput screen of the110,000 compounds in the LDDN drug library to identify new agents that selectively inhibit translation driven by the APP 5'UTR enhancer. These leads may well provide downstream therapeutic anti-amyloid limiting action. Use of our drug hits in RNA gel-shift and APP expression based experiments will probe the pathway of APP translation. IRP-1 and IRP-2 post-transcriptionally control iron homeostasis by modulating ferritin translation and transferrin receptor mRNA stability. HTS hits directed to the 146 nt APP 5'UTR will provide new tools to assess precisely the importance of the interaction of IRP-1 and IRP-2 with 5'UTR of the mRNA encodiing APP (metalloprotein), relative to the mRNAs of other key iron proteins.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Post Transcriptional Control of hemorrhagic iron damage.
  • 批准号:
    8383920
  • 项目类别:
  • 资助金额:
    $25.02万
  • 财政年份:
    2012
  • 负责人:
    JACK T ROGERS
  • 依托单位:
Post Transcriptional Control of hemorrhagic iron damage.
  • 批准号:
    8489367
  • 项目类别:
  • 资助金额:
    $20.77万
  • 财政年份:
    2012
  • 负责人:
    JACK T ROGERS
  • 依托单位:
RNA Targeted Screens of the Prion 5'UTR
  • 批准号:
    8112177
  • 项目类别:
  • 资助金额:
    $5.0万
  • 财政年份:
    2008
  • 负责人:
    JACK T ROGERS
  • 依托单位:
RNA Targeted Screens of the Prion 5'UTR
  • 批准号:
    7617517
  • 项目类别:
  • 资助金额:
    $17.59万
  • 财政年份:
    2008
  • 负责人:
    JACK T ROGERS
  • 依托单位:
国内基金
海外基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
  • 批准号:
    81000622
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2010
  • 负责人:
    梁胜
  • 依托单位:
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
  • 批准号:
    31060293
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    26.0万元
  • 批准年份:
    2010
  • 负责人:
    郭亚芬
  • 依托单位:
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究